BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38378248)

  • 1. Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease.
    Nishikori A; Nishimura MF; Fajgenbaum DC; Nishimura Y; Maehama K; Haratake T; Tabata T; Kawano M; Nakamura N; Momose S; Sumiyoshi R; Koga T; Yamamoto H; van Rhee F; Kawakami A; Sato Y
    J Clin Pathol; 2024 Feb; ():. PubMed ID: 38378248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease.
    Nishikori A; Nishimura MF; Nishimura Y; Otsuka F; Maehama K; Ohsawa K; Momose S; Nakamura N; Sato Y
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
    Gao YH; Liu YT; Zhang MY; Li SY; Fajgenbaum DC; Zhang L; Li J
    Br J Haematol; 2024 May; 204(5):1830-1837. PubMed ID: 38356434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
    Rubenstein AI; Pierson SK; Shyamsundar S; Bustamante MS; Gonzalez MV; Milller ID; Brandstadter JD; Mumau MD; Fajgenbaum DC
    Br J Haematol; 2024 Mar; 204(3):921-930. PubMed ID: 38168727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of IgG4-positive cells in idiopathic multicentric Castleman disease and validation of the 2020 exclusion criteria for IgG4-related disease.
    Nishikori A; Nishimura MF; Nishimura Y; Notohara K; Satou A; Moriyama M; Nakamura S; Sato Y
    Pathol Int; 2022 Jan; 72(1):43-52. PubMed ID: 34762752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of renal biopsy in differentiating idiopathic multicentric Castleman disease from IgG4-related disease.
    Kawanishi M; Kamei F; Sonoda H; Oba M; Fukunaga S; Egawa M; Koyama T; Sato Y; Tanabe K; Ito T
    CEN Case Rep; 2023 May; 12(2):242-248. PubMed ID: 36414812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary Manifestations of Plasma Cell Type Idiopathic Multicentric Castleman Disease: A Clinicopathological Study in Comparison with IgG4-Related Disease.
    Nishimura MF; Igawa T; Gion Y; Tomita S; Inoue D; Izumozaki A; Ubara Y; Nishimura Y; Yoshino T; Sato Y
    J Pers Med; 2020 Dec; 10(4):. PubMed ID: 33321725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
    Nishimura Y; Fajgenbaum DC; Pierson SK; Iwaki N; Nishikori A; Kawano M; Nakamura N; Izutsu K; Takeuchi K; Nishimura MF; Maeda Y; Otsuka F; Yoshizaki K; Oksenhendler E; van Rhee F; Sato Y
    Am J Hematol; 2021 Oct; 96(10):1241-1252. PubMed ID: 34265103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.
    Belyaeva E; Rubenstein A; Pierson SK; Dalldorf D; Frank D; Lim MS; Fajgenbaum DC
    Hematol Oncol; 2022 Apr; 40(2):191-201. PubMed ID: 35104370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
    Kurose N; Futatsuya C; Mizutani KI; Kumagai M; Shioya A; Guo X; Aikawa A; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Yamada S
    Hum Pathol; 2018 Jul; 77():130-138. PubMed ID: 29684500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?
    Fujimoto S; Sakai T; Kawabata H; Kurose N; Yamada S; Takai K; Aoki S; Kuroda J; Ide M; Setoguchi K; Tsukamoto N; Iwao-Kawanami H; Kawanami T; Mizuta S; Fukushima T; Masaki Y
    Am J Hematol; 2019 Sep; 94(9):975-983. PubMed ID: 31222819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman's disease.
    Terasaki Y; Ikushima S; Matsui S; Hebisawa A; Ichimura Y; Izumi S; Ujita M; Arita M; Tomii K; Komase Y; Owan I; Kawamura T; Matsuzawa Y; Murakami M; Ishimoto H; Kimura H; Bando M; Nishimoto N; Kawabata Y; Fukuda Y; Ogura T;
    Histopathology; 2017 Jun; 70(7):1114-1124. PubMed ID: 28207938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome.
    Kurose N; Guo X; Shioya A; Mizutani KI; Kumagai M; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Nakamura S; Yamada S
    Pathol Res Pract; 2019 Oct; 215(10):152563. PubMed ID: 31358479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
    Kurose N; Mizutani KI; Kumagai M; Shioya A; Guo X; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Kida M; Yamada S
    Pathol Res Pract; 2019 Mar; 215(3):410-413. PubMed ID: 30642741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease?
    Nishimura Y; Nishikori A; Sawada H; Czech T; Otsuka Y; Nishimura MF; Mizuno H; Sawa N; Momose S; Ohsawa K; Otsuka F; Sato Y
    J Clin Exp Hematop; 2022 Jun; 62(2):99-105. PubMed ID: 35249898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort.
    Maisonobe L; Bertinchamp R; Damian L; Gérard L; Berisha M; Guillet S; Fieschi C; Malphettes M; Fadlallah J; Hié M; Dunogué B; De Wilde V; Vandergheynst F; Zafrani L; Grall M; Saada N; Garzaro M; Oksenhendler E; Galicier L; Boutboul D
    Br J Haematol; 2022 Feb; 196(3):599-605. PubMed ID: 34585382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome).
    Kageyama C; Igawa T; Gion Y; Iwaki N; Tabata T; Tanaka T; Kondo E; Sakai H; Tsuneyama K; Nomoto K; Noguchi H; Yoshino T; Yokota K; Sato Y
    Pathol Int; 2019 Oct; 69(10):572-579. PubMed ID: 31631463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin G4-related disease and idiopathic multicentric Castleman's disease: confusable immune-mediated disorders.
    Sasaki T; Akiyama M; Kaneko Y; Takeuchi T
    Rheumatology (Oxford); 2022 Feb; 61(2):490-501. PubMed ID: 34363463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy.
    Williams C; Phillips A; Aggarwal V; Slonim LB; Fajgenbaum DC; Karmali R
    Case Rep Oncol; 2021; 14(3):1359-1365. PubMed ID: 34720942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.